Femiguard

Company Overview

Snapshot

Founded in October 2020 by Tovy Sivan and Shlomi Cohen, Femiguard operates with 1–10 employees. The company secured funding in one round from one investor, Sanara Ventures. In June 2026, Femiguard ceased to operate.

Business overview

Femiguard is a Health Tech & Life Sciences company focused on developing medical devices for women's health. Its core product, the Feminity device, is a retrievable fallopian tube occlusion device designed to address hydrosalpinx in infertile women and provide reversible non-hormonal contraception. The device blocks the ostium of the fallopian tube to prevent fluid spillage into the uterine cavity, aiming to increase IVF implantation rates. Femiguard operates within the Medical Devices sector, specifically targeting Medical Treatment & Therapeutics for healthcare providers and women consumers.

Strategic signal

In June 2026, Femiguard ceased operations. This indicates a significant and definitive closure for the company, signaling to investors and the market that its development and commercialization efforts for the Feminity device have concluded.

Company Intelligence Q&A

What is the primary product offered by Femiguard?

Femiguard offers the Feminity device, a retrievable fallopian tube occlusion device designed for infertile women with hydrosalpinx and for women seeking reversible non-hormonal contraception.

When was Femiguard founded and by whom?

Femiguard was founded in October 2020 by Tovy Sivan and Shlomi Cohen.

What is the current operational status of Femiguard?

Femiguard ceased to operate in June 2026.

What problem does the Feminity device aim to solve?

The Feminity device is designed to block the ostium of the fallopian tube, preventing the spillage of undesired fluids into the uterine cavity, which can increase IVF implantation rates and offer a non-hormonal contraceptive option.